PortalPublikationenUpregulation of the heterogeneous nuclear ribonucleoprotein ...

Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers

Standard

Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers. / Möller, Katharina; Wecker, Anna Lena; Höflmayer, Doris; Fraune, Christoph; Makrypidi-Fraune, Georgia; Hube-Magg, Claudia; Kluth, Martina; Steurer, Stefan; Clauditz, Till S; Wilczak, Waldemar; Simon, Ronald; Sauter, Guido; Huland, Hartwig; Heinzer, Hans; Haese, Alexander; Schlomm, Thorsten; Weidemann, Sören; Luebke, Andreas M; Minner, Sarah; Bernreuther, Christian; Bonk, Sarah; Marx, Andreas.

in: VIRCHOWS ARCH, Jahrgang 477, Nr. 5, 11.2020, S. 625-636.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Möller, K, Wecker, AL, Höflmayer, D, Fraune, C, Makrypidi-Fraune, G, Hube-Magg, C, Kluth, M, Steurer, S, Clauditz, TS, Wilczak, W, Simon, R, Sauter, G, Huland, H, Heinzer, H, Haese, A, Schlomm, T, Weidemann, S, Luebke, AM, Minner, S, Bernreuther, C, Bonk, S & Marx, A 2020, 'Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers', VIRCHOWS ARCH, Jg. 477, Nr. 5, S. 625-636. https://doi.org/10.1007/s00428-020-02834-4

APA

Möller, K., Wecker, A. L., Höflmayer, D., Fraune, C., Makrypidi-Fraune, G., Hube-Magg, C., Kluth, M., Steurer, S., Clauditz, T. S., Wilczak, W., Simon, R., Sauter, G., Huland, H., Heinzer, H., Haese, A., Schlomm, T., Weidemann, S., Luebke, A. M., Minner, S., ... Marx, A. (2020). Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers. VIRCHOWS ARCH, 477(5), 625-636. https://doi.org/10.1007/s00428-020-02834-4

Vancouver

Möller K, Wecker AL, Höflmayer D, Fraune C, Makrypidi-Fraune G, Hube-Magg C et al. Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers. VIRCHOWS ARCH. 2020 Nov;477(5):625-636. https://doi.org/10.1007/s00428-020-02834-4

Bibtex

@article{586623ece0d242e1809af43a0ff9313a,
title = "Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers",
abstract = "Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) is a ubiquitous RNA splicing factor that is overexpressed and prognostically relevant in various human cancer types. To study the impact of hnRNPA1 expression in prostate cancer, we analyzed a tissue microarray containing 17,747 clinical prostate cancer specimens by immunohistochemistry. hnRNPA1 was expressed in normal prostate glandular cells but often overexpressed in cancer cells. hnRNPA1 immunostaining was interpretable in 14,258 cancers and considered strong in 33.4%, moderate in 45.9%, weak in 15.3%, and negative in 5.4%. Moderate to strong hnRNPA1 immunostaining was strongly linked to adverse tumor features including high classical and quantitative Gleason score, lymph node metastasis, advanced tumor stage, positive surgical margin, and early biochemical recurrence (p < 0.0001 each). The prognostic impact of hnRNPA1 immunostaining was independent of established preoperatively or postoperatively available prognostic parameters (p < 0.0001). Subset analyses revealed that all these associations were strongly driven by the fraction of cancers lacking the TMPRSS2:ERG gene fusion. Comparison with other key molecular data that were earlier obtained on the same TMA showed that hnRNPA1 overexpression was linked to high levels of androgen receptor (AR) expression (p < 0.0001) as well as presence of 9 of 11 chromosomal deletions (p < 0.05 each). A strong association between hnRNPA1 upregulation and tumor cell proliferation that was independent from the Gleason score supports a role for tumor cell aggressiveness. In conclusion, hnRNPA1 overexpression is an independent predictor of poor prognosis in ERG-negative prostate cancer. hnRNPA1 measurement, either alone or in combination, might provide prognostic information in ERG-negative prostate cancer.",
author = "Katharina M{\"o}ller and Wecker, {Anna Lena} and Doris H{\"o}flmayer and Christoph Fraune and Georgia Makrypidi-Fraune and Claudia Hube-Magg and Martina Kluth and Stefan Steurer and Clauditz, {Till S} and Waldemar Wilczak and Ronald Simon and Guido Sauter and Hartwig Huland and Hans Heinzer and Alexander Haese and Thorsten Schlomm and S{\"o}ren Weidemann and Luebke, {Andreas M} and Sarah Minner and Christian Bernreuther and Sarah Bonk and Andreas Marx",
year = "2020",
month = nov,
doi = "10.1007/s00428-020-02834-4",
language = "English",
volume = "477",
pages = "625--636",
journal = "VIRCHOWS ARCH",
issn = "0945-6317",
publisher = "Springer",
number = "5",

}

RIS

TY - JOUR

T1 - Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers

AU - Möller, Katharina

AU - Wecker, Anna Lena

AU - Höflmayer, Doris

AU - Fraune, Christoph

AU - Makrypidi-Fraune, Georgia

AU - Hube-Magg, Claudia

AU - Kluth, Martina

AU - Steurer, Stefan

AU - Clauditz, Till S

AU - Wilczak, Waldemar

AU - Simon, Ronald

AU - Sauter, Guido

AU - Huland, Hartwig

AU - Heinzer, Hans

AU - Haese, Alexander

AU - Schlomm, Thorsten

AU - Weidemann, Sören

AU - Luebke, Andreas M

AU - Minner, Sarah

AU - Bernreuther, Christian

AU - Bonk, Sarah

AU - Marx, Andreas

PY - 2020/11

Y1 - 2020/11

N2 - Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) is a ubiquitous RNA splicing factor that is overexpressed and prognostically relevant in various human cancer types. To study the impact of hnRNPA1 expression in prostate cancer, we analyzed a tissue microarray containing 17,747 clinical prostate cancer specimens by immunohistochemistry. hnRNPA1 was expressed in normal prostate glandular cells but often overexpressed in cancer cells. hnRNPA1 immunostaining was interpretable in 14,258 cancers and considered strong in 33.4%, moderate in 45.9%, weak in 15.3%, and negative in 5.4%. Moderate to strong hnRNPA1 immunostaining was strongly linked to adverse tumor features including high classical and quantitative Gleason score, lymph node metastasis, advanced tumor stage, positive surgical margin, and early biochemical recurrence (p < 0.0001 each). The prognostic impact of hnRNPA1 immunostaining was independent of established preoperatively or postoperatively available prognostic parameters (p < 0.0001). Subset analyses revealed that all these associations were strongly driven by the fraction of cancers lacking the TMPRSS2:ERG gene fusion. Comparison with other key molecular data that were earlier obtained on the same TMA showed that hnRNPA1 overexpression was linked to high levels of androgen receptor (AR) expression (p < 0.0001) as well as presence of 9 of 11 chromosomal deletions (p < 0.05 each). A strong association between hnRNPA1 upregulation and tumor cell proliferation that was independent from the Gleason score supports a role for tumor cell aggressiveness. In conclusion, hnRNPA1 overexpression is an independent predictor of poor prognosis in ERG-negative prostate cancer. hnRNPA1 measurement, either alone or in combination, might provide prognostic information in ERG-negative prostate cancer.

AB - Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) is a ubiquitous RNA splicing factor that is overexpressed and prognostically relevant in various human cancer types. To study the impact of hnRNPA1 expression in prostate cancer, we analyzed a tissue microarray containing 17,747 clinical prostate cancer specimens by immunohistochemistry. hnRNPA1 was expressed in normal prostate glandular cells but often overexpressed in cancer cells. hnRNPA1 immunostaining was interpretable in 14,258 cancers and considered strong in 33.4%, moderate in 45.9%, weak in 15.3%, and negative in 5.4%. Moderate to strong hnRNPA1 immunostaining was strongly linked to adverse tumor features including high classical and quantitative Gleason score, lymph node metastasis, advanced tumor stage, positive surgical margin, and early biochemical recurrence (p < 0.0001 each). The prognostic impact of hnRNPA1 immunostaining was independent of established preoperatively or postoperatively available prognostic parameters (p < 0.0001). Subset analyses revealed that all these associations were strongly driven by the fraction of cancers lacking the TMPRSS2:ERG gene fusion. Comparison with other key molecular data that were earlier obtained on the same TMA showed that hnRNPA1 overexpression was linked to high levels of androgen receptor (AR) expression (p < 0.0001) as well as presence of 9 of 11 chromosomal deletions (p < 0.05 each). A strong association between hnRNPA1 upregulation and tumor cell proliferation that was independent from the Gleason score supports a role for tumor cell aggressiveness. In conclusion, hnRNPA1 overexpression is an independent predictor of poor prognosis in ERG-negative prostate cancer. hnRNPA1 measurement, either alone or in combination, might provide prognostic information in ERG-negative prostate cancer.

U2 - 10.1007/s00428-020-02834-4

DO - 10.1007/s00428-020-02834-4

M3 - SCORING: Journal article

C2 - 32417965

VL - 477

SP - 625

EP - 636

JO - VIRCHOWS ARCH

JF - VIRCHOWS ARCH

SN - 0945-6317

IS - 5

ER -